JP2019514878A - Ｒｉｐｋ２阻害剤を含むコンジュゲート - Google Patents
Ｒｉｐｋ２阻害剤を含むコンジュゲート Download PDFInfo
- Publication number
- JP2019514878A JP2019514878A JP2018555185A JP2018555185A JP2019514878A JP 2019514878 A JP2019514878 A JP 2019514878A JP 2018555185 A JP2018555185 A JP 2018555185A JP 2018555185 A JP2018555185 A JP 2018555185A JP 2019514878 A JP2019514878 A JP 2019514878A
- Authority
- JP
- Japan
- Prior art keywords
- dimethyl
- tert
- methyl
- oxy
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OUIVOAPQNLMHPF-UHFFFAOYSA-N CC(C)(C)OC(COCCOCCOCCOCCOc1cc2ncnc(Nc3c(C)c(C)n[nH]3)c2cc1S(C(C)(C)C)(=O)=O)=O Chemical compound CC(C)(C)OC(COCCOCCOCCOCCOc1cc2ncnc(Nc3c(C)c(C)n[nH]3)c2cc1S(C(C)(C)C)(=O)=O)=O OUIVOAPQNLMHPF-UHFFFAOYSA-N 0.000 description 1
- OXTCRDFZYCRNGN-UHFFFAOYSA-N CC(C)(C)S(c(c(I)c1)cc2c1ncnc2Nc(c1c2)n[nH]c1ccc2F)(=O)=O Chemical compound CC(C)(C)S(c(c(I)c1)cc2c1ncnc2Nc(c1c2)n[nH]c1ccc2F)(=O)=O OXTCRDFZYCRNGN-UHFFFAOYSA-N 0.000 description 1
- KMYVGYGXTVQQGH-UHFFFAOYSA-N CC(C)(C)S(c(c(OC)cc1ncc2)cc1c2Nc(c1c2)n[nH]c1ccc2F)(=O)=O Chemical compound CC(C)(C)S(c(c(OC)cc1ncc2)cc1c2Nc(c1c2)n[nH]c1ccc2F)(=O)=O KMYVGYGXTVQQGH-UHFFFAOYSA-N 0.000 description 1
- UPEKBIRBSCRSGG-UHFFFAOYSA-N CC(C)(C)S(c(cc1c(Nc2n[nH]c(C)c2C)ncnc1c1)c1I)(=O)=O Chemical compound CC(C)(C)S(c(cc1c(Nc2n[nH]c(C)c2C)ncnc1c1)c1I)(=O)=O UPEKBIRBSCRSGG-UHFFFAOYSA-N 0.000 description 1
- ZJDSRNGAMQCPSQ-RUZDIDTESA-N CC(C)(C)S(c1cc2c(Nc3c(C)c(C)n[nH]3)ncnc2cc1OCCCN(CC1)CCN1c(nc1)ncc1OC[C@@H]1OCCNC1)(=O)=O Chemical compound CC(C)(C)S(c1cc2c(Nc3c(C)c(C)n[nH]3)ncnc2cc1OCCCN(CC1)CCN1c(nc1)ncc1OC[C@@H]1OCCNC1)(=O)=O ZJDSRNGAMQCPSQ-RUZDIDTESA-N 0.000 description 1
- YICXXAFBGZWWRF-BVHINDKJSA-N CC(CN(CC(N(CC1(C)C)C(C=C2Cc(cc3)ccc3F)=C1N(C)C2=O)=O)[C@@H](CCl)C1)N1C(OC(C)(C)C)=O Chemical compound CC(CN(CC(N(CC1(C)C)C(C=C2Cc(cc3)ccc3F)=C1N(C)C2=O)=O)[C@@H](CCl)C1)N1C(OC(C)(C)C)=O YICXXAFBGZWWRF-BVHINDKJSA-N 0.000 description 1
- RZGDYOYVXRUHTB-WYUQMFHNSA-N CCCC(C(CC(C(C(C)(C)C1)N)N1C(CN1[C@@H](CN2[C@H](C)CN(C)CC2)CN[C@H](C)C1)O)F)=O Chemical compound CCCC(C(CC(C(C(C)(C)C1)N)N1C(CN1[C@@H](CN2[C@H](C)CN(C)CC2)CN[C@H](C)C1)O)F)=O RZGDYOYVXRUHTB-WYUQMFHNSA-N 0.000 description 1
- HKTZDTYDOGDNFP-JHVJFLLYSA-N C[C@@H](C(N[C@@H](C(CC1)CCN1I)C(N(CCC1)[C@@H]1c1nc(C(c(cc2)ccc2F)=O)c[s]1)=O)=O)SNC Chemical compound C[C@@H](C(N[C@@H](C(CC1)CCN1I)C(N(CCC1)[C@@H]1c1nc(C(c(cc2)ccc2F)=O)c[s]1)=O)=O)SNC HKTZDTYDOGDNFP-JHVJFLLYSA-N 0.000 description 1
- AFNOYHGDZRTMHH-VAHYAAKGSA-N C[C@@H]1C(NC)SC1C(N[C@H](C(N(CCC1)C1c1nc(C(c(cc2)ccc2F)=O)c[s]1)=O)I)=O Chemical compound C[C@@H]1C(NC)SC1C(N[C@H](C(N(CCC1)C1c1nc(C(c(cc2)ccc2F)=O)c[s]1)=O)I)=O AFNOYHGDZRTMHH-VAHYAAKGSA-N 0.000 description 1
- AFIJMXFBOQXXCA-SCYJZORYSA-N C[C@H](C1)N(C[C@@H](C2)N(CC(N(CC3(C)C)c4c3ncc(Cc(cc3)ccc3F)c4)=O)C[C@@H](C)N2C(OC(C)(C)C)=O)CCN1c1ncnc(N2CCC(COc3cc4ncnc(Nc5c(C)c(C)n[nH]5)c4cc3S(C(C)(C)C)(=O)=O)CC2)c1 Chemical compound C[C@H](C1)N(C[C@@H](C2)N(CC(N(CC3(C)C)c4c3ncc(Cc(cc3)ccc3F)c4)=O)C[C@@H](C)N2C(OC(C)(C)C)=O)CCN1c1ncnc(N2CCC(COc3cc4ncnc(Nc5c(C)c(C)n[nH]5)c4cc3S(C(C)(C)C)(=O)=O)CC2)c1 AFIJMXFBOQXXCA-SCYJZORYSA-N 0.000 description 1
- ABHAHZMDPOIEDZ-LGVFNWMJSA-N C[C@H](C1)N(C[C@@H](C2)N(Cc3ccccc3)C[C@@H](C)N2C(OC(C)(C)C)=O)CCN1c(nc1)ncc1C(O)=O Chemical compound C[C@H](C1)N(C[C@@H](C2)N(Cc3ccccc3)C[C@@H](C)N2C(OC(C)(C)C)=O)CCN1c(nc1)ncc1C(O)=O ABHAHZMDPOIEDZ-LGVFNWMJSA-N 0.000 description 1
- AQOXKTRVDHOLQC-SGTPKBLHSA-O C[C@H](C1)NCCN1c1ncc(C(N2CCN(CCCOc3cc4ncnc(N/C(/N)=C(\C)/C(C)=[NH2+])c4cc3S(C(C)(C)C)(=O)=O)CC2)=O)nc1 Chemical compound C[C@H](C1)NCCN1c1ncc(C(N2CCN(CCCOc3cc4ncnc(N/C(/N)=C(\C)/C(C)=[NH2+])c4cc3S(C(C)(C)C)(=O)=O)CC2)=O)nc1 AQOXKTRVDHOLQC-SGTPKBLHSA-O 0.000 description 1
- TUDAIQXEXWEJSX-GKDAEUHQSA-N C[C@H](CN(CC(N(CC1(C)C)c2c1ncc(Cc(cc1)ccc1F)c2)=O)[C@@H](CN(CC1)CCC1(CC1)CCN1c(nc1)ncc1OCCOc1cc2ncnc(Nc3c(C)c(C)n[nH]3)c2cc1S(C(C)(C)C)(=O)=O)C1)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC(N(CC1(C)C)c2c1ncc(Cc(cc1)ccc1F)c2)=O)[C@@H](CN(CC1)CCC1(CC1)CCN1c(nc1)ncc1OCCOc1cc2ncnc(Nc3c(C)c(C)n[nH]3)c2cc1S(C(C)(C)C)(=O)=O)C1)N1C(OC(C)(C)C)=O TUDAIQXEXWEJSX-GKDAEUHQSA-N 0.000 description 1
- HAJFSBLTRBYPBB-BTYSJIOQSA-N C[C@H](CN(CC(N(CC1(C)C)c2c1ncc(Cc(cc1)ccc1F)c2)=O)[C@@H](CN(Cc(cc1)c2cc1C(O)=O)C2=O)C1)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC(N(CC1(C)C)c2c1ncc(Cc(cc1)ccc1F)c2)=O)[C@@H](CN(Cc(cc1)c2cc1C(O)=O)C2=O)C1)N1C(OC(C)(C)C)=O HAJFSBLTRBYPBB-BTYSJIOQSA-N 0.000 description 1
- NJKQGJDEAVRMFM-SNVBAGLBSA-N C[C@H](CN(CC1)c2ncc(C(O)=O)nc2)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC1)c2ncc(C(O)=O)nc2)N1C(OC(C)(C)C)=O NJKQGJDEAVRMFM-SNVBAGLBSA-N 0.000 description 1
- QTDNLRUKJLHPDH-LLVKDONJSA-N C[C@H](CN(CC1)c2ncc(C(OC)=O)nc2)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC1)c2ncc(C(OC)=O)nc2)N1C(OC(C)(C)C)=O QTDNLRUKJLHPDH-LLVKDONJSA-N 0.000 description 1
- QGEFRGPCFOEDNF-RKDXNWHRSA-N C[C@H](CO[C@@H](CO)C1)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CO[C@@H](CO)C1)N1C(OC(C)(C)C)=O QGEFRGPCFOEDNF-RKDXNWHRSA-N 0.000 description 1
- FHXRDTNNYDGAJE-VGOKPJQXSA-N C[C@H]1NCC(CN(CC2)CCC2I)N(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 Chemical compound C[C@H]1NCC(CN(CC2)CCC2I)N(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 FHXRDTNNYDGAJE-VGOKPJQXSA-N 0.000 description 1
- CWZDXAGKRYGKPI-NFQZSHQESA-N C[C@H]1NCC(CN(CC2)[C@H](C)CN2I)N(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 Chemical compound C[C@H]1NCC(CN(CC2)[C@H](C)CN2I)N(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 CWZDXAGKRYGKPI-NFQZSHQESA-N 0.000 description 1
- SWCJOVQPUSQXRD-DVECYGJZSA-N C[C@H]1NCCN(C/C(/N(CCC2)[C@@H]2c2nc(C(c(cc3)ccc3F)=O)c[s]2)=[O]\CN(CC2)CCC2I)C1 Chemical compound C[C@H]1NCCN(C/C(/N(CCC2)[C@@H]2c2nc(C(c(cc3)ccc3F)=O)c[s]2)=[O]\CN(CC2)CCC2I)C1 SWCJOVQPUSQXRD-DVECYGJZSA-N 0.000 description 1
- CWZDXAGKRYGKPI-LDJSFYOUSA-N C[C@H]1NC[C@H](CN(CC2)C(C)CN2I)N(CC(N2c3cc(Cc(cc4)ccc4F)cnc3C(C)(C)C2)=O)C1 Chemical compound C[C@H]1NC[C@H](CN(CC2)C(C)CN2I)N(CC(N2c3cc(Cc(cc4)ccc4F)cnc3C(C)(C)C2)=O)C1 CWZDXAGKRYGKPI-LDJSFYOUSA-N 0.000 description 1
- YSQAXUMUHHUFOP-CCTQEFEQSA-N C[C@H]1NC[C@H](CN(CC2)[C@H](C)CN2I)N(CC(N(CC2(C)C)c3c2ncc(C(c(cc2)ccc2F)O)c3)=O)C1 Chemical compound C[C@H]1NC[C@H](CN(CC2)[C@H](C)CN2I)N(CC(N(CC2(C)C)c3c2ncc(C(c(cc2)ccc2F)O)c3)=O)C1 YSQAXUMUHHUFOP-CCTQEFEQSA-N 0.000 description 1
- VERIXCSQGXBNPV-AQLHNQTESA-N C[C@H]1NC[C@H](CN(CC2)[C@H](C)CN2c(nc2)ncc2OCCOc2cc3ncnc(Nc4c(C)c(C)n[nH]4)c3cc2S(C(C)(C)C)(=O)=O)N(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 Chemical compound C[C@H]1NC[C@H](CN(CC2)[C@H](C)CN2c(nc2)ncc2OCCOc2cc3ncnc(Nc4c(C)c(C)n[nH]4)c3cc2S(C(C)(C)C)(=O)=O)N(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 VERIXCSQGXBNPV-AQLHNQTESA-N 0.000 description 1
- OLWKVJMWNFCFHC-ZZNFJVAJSA-N C[C@H]1NC[C@H](CN(CCO2)C[C@@H]2I)N(CC(N(CCC2)[C@@H]2c2nc(C(c(cc3)ccc3F)=O)c[s]2)=O)C1 Chemical compound C[C@H]1NC[C@H](CN(CCO2)C[C@@H]2I)N(CC(N(CCC2)[C@@H]2c2nc(C(c(cc3)ccc3F)=O)c[s]2)=O)C1 OLWKVJMWNFCFHC-ZZNFJVAJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324944P | 2016-04-20 | 2016-04-20 | |
| US62/324,944 | 2016-04-20 | ||
| PCT/EP2017/059090 WO2017182418A1 (en) | 2016-04-20 | 2017-04-18 | Conjugates comprising ripk2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019514878A true JP2019514878A (ja) | 2019-06-06 |
| JP2019514878A5 JP2019514878A5 (enExample) | 2020-05-28 |
Family
ID=58548715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555185A Pending JP2019514878A (ja) | 2016-04-20 | 2017-04-18 | Ｒｉｐｋ２阻害剤を含むコンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10781205B2 (enExample) |
| EP (1) | EP3445759A1 (enExample) |
| JP (1) | JP2019514878A (enExample) |
| KR (1) | KR20180135038A (enExample) |
| CN (1) | CN109311867A (enExample) |
| AU (1) | AU2017253560B2 (enExample) |
| BR (1) | BR112018071408A2 (enExample) |
| CA (1) | CA3020792A1 (enExample) |
| RU (1) | RU2018134981A (enExample) |
| WO (1) | WO2017182418A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024071371A1 (ja) * | 2022-09-30 | 2024-04-04 | ユビエンス株式会社 | 複素環式化合物 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| CA3103185A1 (en) * | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| CN112638905A (zh) * | 2018-08-28 | 2021-04-09 | 南京明德新药研发有限公司 | 作为rip2激酶抑制剂的喹唑啉类衍生物 |
| KR20210141554A (ko) | 2019-03-21 | 2021-11-23 | 코디악 바이오사이언시즈, 인크. | 세포외 소포 접합체 및 이의 용도 |
| EP3941607A1 (en) | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Process for preparing extracellular vesicles |
| JP7764027B2 (ja) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | 複素環化合物 |
| JP2021024787A (ja) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| TW202221000A (zh) | 2020-09-30 | 2022-06-01 | 英屬開曼群島商百濟神州有限公司 | 用於降解ｅｇｆｒ之雙功能化合物及相關使用方法 |
| CN116847848A (zh) | 2021-02-10 | 2023-10-03 | 百济神州有限公司 | Egfr降解剂和使用方法 |
| CN114014890A (zh) * | 2021-03-12 | 2022-02-08 | 爱科诺生物医药(香港)有限公司 | 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用 |
| EP4330251A4 (en) | 2021-04-30 | 2025-03-05 | BeiGene Switzerland GmbH | EGFR DEGRADING AGENTS AND METHODS OF USE THEREOF |
| CA3240051A1 (en) | 2021-12-30 | 2023-07-06 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2024246838A1 (en) | 2023-05-31 | 2024-12-05 | Beigene Switzerland Gmbh | Compounds for the degradation of egfr kinase |
| WO2025092821A1 (zh) * | 2023-11-01 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | 喹唑啉衍生物类ripk2抑制剂及其用途 |
| CN122270449A (zh) | 2023-12-13 | 2026-06-23 | 百济神州(苏州)生物科技有限公司 | 通过将irak4抑制剂与e3连接酶配体缀合来降解irak4以及使用方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011524339A (ja) * | 2008-05-16 | 2011-09-01 | ノバルティス アーゲー | Ｉａｐ阻害剤による免疫調節 |
| JP2014514317A (ja) * | 2011-04-21 | 2014-06-19 | アステックス、セラピューティックス、リミテッド | 二環式複素環化合物および治療法におけるその使用 |
| JP2014515730A (ja) * | 2011-03-04 | 2014-07-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | キナーゼ阻害剤としてのアミノキノリン |
| JP2014525937A (ja) * | 2011-08-18 | 2014-10-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | キナーゼ阻害剤としてのアミノキナゾリン |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110217A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| WO2008128171A2 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| MX351274B (es) | 2009-08-12 | 2017-10-06 | Novartis Ag | Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis. |
| JP2013526484A (ja) | 2010-05-07 | 2013-06-24 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのアミノ‐キノリン |
| UY33549A (es) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| AU2013306087B2 (en) | 2012-08-23 | 2017-08-10 | The Regents Of The University Of Michigan | Bivalent inhibitors of IAP proteins and therapeutic methods using the same |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| US9603889B2 (en) | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| CN104854100B (zh) | 2012-12-11 | 2017-05-24 | 霍夫曼-拉罗奇有限公司 | 二聚化合物 |
| KR101335240B1 (ko) | 2012-12-13 | 2013-11-29 | 전호건 | 수평 연속 방식의 탄화장치 |
| CN105143208B (zh) * | 2013-02-21 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的喹唑啉 |
| GB201311888D0 (en) * | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) * | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
-
2017
- 2017-04-18 AU AU2017253560A patent/AU2017253560B2/en not_active Ceased
- 2017-04-18 BR BR112018071408A patent/BR112018071408A2/pt not_active Application Discontinuation
- 2017-04-18 RU RU2018134981A patent/RU2018134981A/ru not_active Application Discontinuation
- 2017-04-18 CN CN201780036566.1A patent/CN109311867A/zh active Pending
- 2017-04-18 KR KR1020187033631A patent/KR20180135038A/ko not_active Withdrawn
- 2017-04-18 WO PCT/EP2017/059090 patent/WO2017182418A1/en not_active Ceased
- 2017-04-18 EP EP17717721.9A patent/EP3445759A1/en not_active Withdrawn
- 2017-04-18 US US16/094,564 patent/US10781205B2/en not_active Expired - Fee Related
- 2017-04-18 CA CA3020792A patent/CA3020792A1/en not_active Abandoned
- 2017-04-18 JP JP2018555185A patent/JP2019514878A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011524339A (ja) * | 2008-05-16 | 2011-09-01 | ノバルティス アーゲー | Ｉａｐ阻害剤による免疫調節 |
| JP2014515730A (ja) * | 2011-03-04 | 2014-07-03 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | キナーゼ阻害剤としてのアミノキノリン |
| JP2014514317A (ja) * | 2011-04-21 | 2014-06-19 | アステックス、セラピューティックス、リミテッド | 二環式複素環化合物および治療法におけるその使用 |
| JP2014525937A (ja) * | 2011-08-18 | 2014-10-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | キナーゼ阻害剤としてのアミノキナゾリン |
Non-Patent Citations (1)
| Title |
|---|
| BONDESON, DANIEL P.; MARES, ALINA; SMITH, IAN E. D.; KO, EUNHWA; CAMPOS, SEBASTIEN; MIAH, AFJAL: "Catalytic in vivo protein knockdown by small-molecule PROTACs", NATURE CHEMICAL BIOLOGY, vol. 11(8),, JPN6021008555, 2015, pages 611 - 617, ISSN: 0004462839 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024071371A1 (ja) * | 2022-09-30 | 2024-04-04 | ユビエンス株式会社 | 複素環式化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017182418A1 (en) | 2017-10-26 |
| CN109311867A (zh) | 2019-02-05 |
| US20190119271A1 (en) | 2019-04-25 |
| RU2018134981A (ru) | 2020-05-20 |
| AU2017253560B2 (en) | 2019-03-21 |
| BR112018071408A2 (pt) | 2019-02-05 |
| CA3020792A1 (en) | 2017-10-26 |
| EP3445759A1 (en) | 2019-02-27 |
| AU2017253560A1 (en) | 2018-11-08 |
| KR20180135038A (ko) | 2018-12-19 |
| US10781205B2 (en) | 2020-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107709305B (zh) | 新型化合物 | |
| AU2017253560B2 (en) | Conjugates comprising RIPK2 inhibitors | |
| JP7005582B2 (ja) | ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物 | |
| TWI618706B (zh) | 用作ａｔｒ激酶抑制劑之化合物 | |
| KR20220004100A (ko) | 안드로겐 수용체를 표적 분해하는 이중 기능성의 키메라 헤테로 고리 화합물 및 이의 용도 | |
| WO2022228547A1 (zh) | 一种膦酰衍生物及其组合物和药学上的应用 | |
| WO2021136354A1 (zh) | 联苯类衍生物抑制剂、其制备方法和应用 | |
| WO2023066363A1 (zh) | Parp-1降解剂及其用途 | |
| TW201602100A (zh) | 選擇性經取代之喹啉化合物 | |
| KR20190035937A (ko) | 약학적 화합물 | |
| WO2022111526A1 (zh) | 一种苯环衍生物及其组合物和药学上的应用 | |
| WO2024067691A1 (zh) | 含氮杂环类化合物及其医药用途 | |
| WO2023125877A1 (zh) | 三并环类衍生物抑制剂、其制备方法和应用 | |
| WO2024125532A1 (zh) | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 | |
| WO2024067818A1 (zh) | 一种用于bcl-2蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 | |
| WO2024175024A1 (zh) | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 | |
| WO2023093728A1 (zh) | Brm选择性降解剂化合物及其应用 | |
| WO2025061035A1 (zh) | Brm选择性降解剂化合物及其应用 | |
| HK40049641A (en) | Biphenyl derivative inhibitor, preparation method therefor and use | |
| HK40055574B (en) | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease | |
| HK1256857B (en) | Polyfluorinated compounds acting as bruton's tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200414 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200414 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210304 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210316 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211012 |